ArticleFrontiers in aging neuroscience2024
Higher soluble TREM-1 levels are associated with cognitive impairment after acute ischemic stroke.
Article in Frontiers in aging neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Blood-Based Biomarkers for Post-Stroke Cognitive Impairment.Current issues in molecular biology · 2026Review
- Molecular biomarkers of cognitive impairment and neuropsychiatric symptoms after stroke in late-life-enriched cohorts: a scoping review.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Triggering receptor expressed on myeloid cells-1 (TREM-1) was reported to be critical for mediating the neurological function after stroke, while the impact of soluble TREM-1 (sTREM-1) on cognitive impairment after ischemic stroke is unclear. We aimed to explore the association between sTREM-1 and post-stroke cognitive impairment (PSCI). Methods: We prospectively recruited consecutive ischemic stroke patients who admitted hospital within 7 days of onset. Serum sTREM-1 concentrations were measured after admission. Cognitive function was assessed at 90 days follow-up using the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA). PSCI was defined as a MMSE score of <27 or a MoCA score < 26. Results: A total of 291 patients (mean age, 66.6 years; 46.0% female) were enrolled for this study. Among these participants, the median sTREM-1 concentrations were 289.4 pg/mL. According to the MoCA score, 153 (52.6%) patients experienced PSCI at 3 months. After adjustment for confounding risk factors by multivariate regression analysis, patients with sTREM-1 levels in the fourth quartile were more likely to have increased risk 3-month PSCI (as compared with the first quartile, odds ratio 12.22, 95% confidence intervals, 5.20-28.71, Conclusion: Our study revealed that higher serum sTREM-1 levels at admission were associated with increased risk of 3-month PSCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.